56717-04-5

Basic information

• Product Name: 1,2,3,4-Tetrahydro-acridin-9-ol
• Synonyms: 1,2,3,4-Tetrahydro-acridin-9-ol
• CAS NO: 56717-04-5
• Molecular Formula: C₁₃H₁₃NO
• Molecular Weight: 199.24842
• Mol File: 56717-04-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,3,4-Tetrahydro-acridin-9-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-Tetrahydro-acridin-9-ol(56717-04-5)
• EPA Substance Registry System: 1,2,3,4-Tetrahydro-acridin-9-ol(56717-04-5)

Safety Data

• Hazardous Substances Data: 56717-04-5(Hazardous Substances Data)

Upstream product

• 108-94-1 cyclohexanone 
• 118-92-3 anthranilic acid 
• 13161-85-8 1,2,3,4,9,10-hexahydroacridin-9-one 
• 3898-08-6 1,1-diphenylthiourea 
• 6833-04-1 N,N'-Diphenylpimelamide 
• 14807-16-0 9-Anilino-1,2,3,4-tetrahydroacridine 
• 38778-79-9 ethyl 2-(N-phenylamino)-1-cyclohexene-1-carboxylate 

Downstream Products

• 5396-30-5 9-chloro-1,2,3,4-tetrahydroacridine 
• 443662-39-3 7-bromo-1,2,3,4-tetrahydro-acridin-9-ol 
• 578-95-0 10H-acridin-9-one 
• 7032-37-3 4-Morpholino-2,3-tetramethylenequinoline 
• 53618-67-0 6-Brom-4-chlor-2,3-tetramethylenchinolin 
• 321-64-2 tacrin 
• 260-94-6 acridine 

Relevant articles and documents

Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity

A series of tacrine-ebselen hybrids were synthesised and evaluated as possible multifunctional anti-Alzheimer's disease (AD) agents. Compound 6i, which is tacrine linked with 5,6-dimethoxybenzo[d][1,2]selenazol-3(2H)-one by a six-carbon spacer, was the most potent acetylcholinesterase (AChE) and butylcholinesterase (BuChE) inhibitor, with IC50 values of 2.55 and 2.80 nM, respectively. Furthermore, this compound demonstrated similar hydrogen peroxide and peroxynitrite scavenging activity as ebselen by horseradish peroxidase assay and peroxynitrite scavenging activity assay, indicating that this hybrid is a good multifunctional drug candidate for the treatment of AD.